Decreased infiltration of macrophages and inhibited activation of nuclear factor-kappa B in blood vessels: A possible mechanism for the anti-atherogenic effects of losartan

Acta Cardiologica

Volumn 62, Issue 6, 2007, Pages 607-613

  Xu, Hong Xin ^a   Li, Jian Jun ^b   Li, Geng Shan ^a   Wang, Jing ^a   Li, Ning Xu ^a   Peng, Jun ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b FUWAI HOSPITAL   (China)

Author keywords

AT1 receptor antagonist; Atherosclerosis; Losartan; Macrophage; Nuclear factor kappa B

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LIPID; LOSARTAN;

ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL INFILTRATION; CONTROLLED STUDY; DRUG MECHANISM; GENE TARGETING; HEART INJURY; LIPID BLOOD LEVEL; MACROPHAGE; NONHUMAN; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ATHEROSCLEROSIS; CELL MIGRATION INHIBITION; DISEASE MODELS, ANIMAL; LIPIDS; LOSARTAN; MACROPHAGES; MALE; NF-KAPPA B; RABBITS; RANDOM ALLOCATION;

EID: 37049003766     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.62.6.2024021     Document Type: Article

References (31)

1. Weiss D, Kools JJ, Taylor WR. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 2001; 103: 448-54.
2. Ferrario CM, Deitch JS, Dean RH, Strawn WB. Hypertension and atherosclerosis: a mechanistic understanding of disease progression. Cardiovasc Risk Factors 1996; 6: 299-310.
3. Clozel M, Kuhn H, Hefti F, Baumgartner HR. Endothelial dysfunction and subendothelial monocyte macrophages in hypertension. Hypertension 1991; 18: 132-41.
4. Kim JA, Berliner JA, Nadler JL. Angiotensin II increases monocyte binding to endothelial cells. Biochem Biophys Res Commun 1996; 226: 862-8.
5. Kubo A, Fukuda N, Soma M, Izumi Y, Kanmatsuse K. Inhibitory effect of an angiotensin II type 1 receptor antagonist on growth of vascular smooth muscle cells from spontaneously hypertensive rats. J Cardiovasc Pharmacol 1996; 27: 58-63.
6. Yanagitani Y, Rakugi A, Okamura A, Moriguchi K, Takiuchi S, Ohishi M, Suzuki K, Higaki J, Ogihara T. Angiotensin II type 1 receptor-mediated peroxide production in human macrophages. Hypertension 1999; 33(1 pt 2): 355-9.
7. Keidar S, Kaplan M, Aviram M. Angiotensin II-modified LDL is taken up by macrophages via the scavenger receptor leading to cellular cholesterol accumulation. Arterioscler Thromb Vasc Biol 1996; 16: 97-105.
8. Miura T, Komori M, Takahashi T, Shiota K. Computerized three-dimensional reconstruction of human embryos and their organs using the "NIH image" software [in Japanese]. Kaiboguku Zasshi 1995; 70: 353-61.
9. Tan D, Cernadas MR, Aragyncillo P, Castilla MA. Role of nitric oxide-related mechanisms in renal function in aging rats. Nephrol Dial Transplant 1998; 13: 594-601.
10. Tsukada T, Rosenfeld ME, Ross R, Gown AM. Immunocytochemical analysis of cellular components in atherosclerotic lesions: use of monoclonal antibodies with the Watanabe and fat-fed rabbit. Arteriosclerosis 1986; 6: 601-13.
11. Hernandez-Presa M, Bustos C, Ortego M, Tunon J, Renedo G, Ruiz-Ortega M, Egido J. Angiotensin-Converting enzyme inhibition prevents arterial nuclear factor-κB activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997; 95: 1532-41.
12. Bourcier T, Sukhova G, Libby P. The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem 1997; 272: 15817-24.
13. Hope S, Brecher P, Chobanian AV. Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis. Am J Hypertens 1999; 12: 28-34.
14. Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 2000; 101: 1586-93.
15. 1 receptor antagonist reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits. Hypertension 1999; 34(part2): 969-75.
16. Li J, Hirose N, Kawamura M, Arai Y. Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits. Atherosclerosis 1999; 143: 315-26.
17. Kockx MM, De Meyer GY, Buyssens N, Knaapen MM, BuIt H, Herman AG. Cell composition, replication, and apoptosis in atherosclerotic plaques after 6 months of cholesterol withdrawal. Circ Res 1998; 83: 378-87.
18. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
19. Goetzl EJ, Klickstein LB, Watt KWK, Wintroub BU. The preferential human mononuclear chemotactic activity of the substituent peptides of angiotensin II. Biochem Biophys Res Commun 1980; 97: 1097-102.
20. Kim JA, Berliner JA, Nadler JL. Angiotensin II increases monocyte binding to aortic endothelial cells. Clin Res 1994; 42: 15A.
21. Weinstock JV, Blum AM. Isolated liver granulomas of murine Schistosoma mansoni contain components of the angiotensin system. J Immunol 1983; 131: 2529-32.
22. Baeuerle PA, Henkel T. Function and activation of NF-κB in the immune system. Annu Rev Immunol 1994; 12: 141-79.
23. Lenardo MJ, Baltimore D. NF-κB: a pleiotropic mediator of inducible and tissue-specific gene control. Cell 1989; 58: 227-9.
24. Baeuerle PA, Baltimore D. IκB: a specific inhibitor of the NF-κB transcription factor. Science 1988; 242: 540-6.
25. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 1996; 97: 1715-22.
26. Ritchie ME. Nuclear factor-κB selectively and markedly activated in humans with unstable angina pectoris. Circulation 1998; 98: 1707-13.
27. Ortego M, Bustos C, Hernández-Presa MA, Tuñón J, Díaz C, Hernández G, Egido J. Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999; 147: 253-61.
28. Kothe H, Dalhoff K, Rupp J, Muller A, Kreuzer J, Maass M, Katus HA. Hydroxymethylglutaryl co-enzyme A reductase inhibitors modify inflammatory response of human macrophages and endothelial cells infected with chlamydia pneumoniae. Circulation 2000; 101: 1760-3.
29. Kranzhofer R, Schmidt J, Pfeiffer CAH, Hagl S, Libby P, Kubler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999; 19: 1623-9.
30. Wilson SH, Caplice NM, Simari RD, Holmes DR, Carlson PJ, Lerman A. Activated nuclear factor-κB is present in the coronary vasculature in experimental hypercholesterolemia. Atherosclerosis 2000; 148: 23-30.
31. Kaltschmidt C, Kaltschmidt B, Neumann H, Wekerle H, Baeuerle PA. Constitutive NF-κB activity in neurons. Mol Cell Biol 1994; 14: 3981-92.